Edge Therapeutics, Inc. (35)

Browse by Contract Category

Contracts

Share Transfer Agreement by and between PDS Biotechnology Corporation and Merck KGaA, Darmstadt, Germany (Filed With SEC on January 3, 2023)
First Amendment to Preclinical/Clinical Collaboration and License Agreement dated as of November 22, 2021 by and between PDS Biotechnology Corporation and Farmacore Biotechnology (Filed With SEC on August 8, 2022)
Executive Employment Agreement by and between Spencer Brown and PDS Biotechnology Corporation, effective as of June 1, 2022 (Filed With SEC on August 8, 2022)
PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on May 18, 2022)
Patent License Agreement dated as of November 5, 2021, by and between PDS Biotechnology Corporation and the U.S. Department of Health and Human Services, as represented by the... (Filed With SEC on March 31, 2022)
Sublease Agreement, effective as of March 5, 2020, by and between PDS Biotechnology Corporation and COWI North America, Inc (Filed With SEC on March 27, 2020)
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of January 24, 2019, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS... (Filed With SEC on January 30, 2019)
Venture Loan and Security Agreement, dated August 24, 2022, by and among Horizon Technology Finance Corporation, as a lender and collateral agent, Powerscourt Investments XXV, LP,... (Filed With SEC on November 14, 2022)
Form of Warrant issued under the Venture Loan and Security Agreement, dated August 24, 2022 (Filed With SEC on November 14, 2022)
Amended and Restated Preclinical/Clinical Collaboration and License Agreement dated as of November 30, 2020 by and between PDS Biotechnology Corporation and Farmacore Biotechnology (Filed With SEC on August 8, 2022)
PDS Biotechnology Corporation Change of Control Severance Plan effective as of March 14, 2022 (Filed With SEC on March 31, 2022)
Option Agreement with University of Georgia Research Foundation, Inc. effective as of October 25, 2021 (Filed With SEC on March 31, 2022)
Executive Employment Agreement by and between Lauren V. Wood, M.D. and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)
Amended and Restated Executive Employment Agreement by and between Frank K. Bedu-Addo and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)
Executive Employment Agreement by and between Gregory Conn, Ph.D. and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)
Executive Employment Agreement by and between Matthew Hill and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)
Executive Employment Agreement by and between PDS Biotechnology Corporation and Matthew Hill, dated as of October 4, 2021 (Filed With SEC on October 6, 2021)
Amendment to Employment Agreement by and between PDS Biotechnology Corporation and Gregory Conn, Ph.D., effective as of June 17, 2021 (Filed With SEC on June 21, 2021)
Underwriting Agreement, dated June 15, 2021, by and among PDS Biotechnology Corporation and Cantor Fitzgerald & Co (Filed With SEC on June 17, 2021)
Form of Employee Stock Option Agreement under the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (Filed With SEC on December 9, 2020)
PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on December 9, 2020)
Executive Employment Agreement by and between the Company and Seth L. Van Voorhees, Ph.D (Filed With SEC on December 9, 2020)
Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (Filed With SEC on December 9, 2020)
Underwriting Agreement dated August 11, 2020 (Filed With SEC on August 13, 2020)
Consulting Agreement (Michael King) (Filed With SEC on June 24, 2020)
Description of Securities (Filed With SEC on March 27, 2020)
Form of Underwriting Agreement (Filed With SEC on January 17, 2020)
Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement, dated as of October 28, 2019, by and between PDS Biotechnology Corporation and MSD International GmbH (Filed With SEC on November 7, 2019)
Offer Letter, dated February 1, 2019, by and between PDS Biotechnology Corporation and Lauren V. Wood, M.D (Filed With SEC on August 1, 2019)
Employment Agreement, effective June 1, 2019, by and between PDS Biotechnology Corporation and Gregory Conn (Filed With SEC on August 1, 2019)
Common Stock Purchase Agreement, dated July 29, 2019 between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)
Registration Rights Agreement, dated July 29, 2019, between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)
PDS Biotechnology Corporation 2019 Inducement Plan (Filed With SEC on June 20, 2019)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Inducement Plan (Filed With SEC on June 20, 2019)
Letter Agreement, dated as of February 3, 2019, by and among Edge Therapeutics, Inc., PDS Biotechnology Corporation and Brian A. Leuthner (Filed With SEC on February 4, 2019)